PureCycle Technologies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PureCycle Technologies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.36M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Feb 26, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($182.57M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($289.14M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($101.72M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($84.75M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($77.50M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | ($52.99M) | Mar 16, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($181.44M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($145.38M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($113.90M) | Feb 26, 2026 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.93M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.48M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $6.62M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $4.35M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $3.69M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $648.0K | Mar 16, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.48M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $53.14M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $55.26M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $53.24M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $57.62M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $27.97M | Mar 16, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($142.74M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($144.83M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($94.91M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($65.48M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($54.51M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | ($17.95M) | Mar 16, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.85M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $55.58M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $153.90M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $287.19M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $137.39M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $29.81M | Mar 16, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $922.67M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $798.39M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.04B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $861.34M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $664.68M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $407.98M | Mar 29, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $572.08M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $617.94M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $619.14M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $350.45M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $283.15M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $296.23M | Mar 29, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.89M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $180.45M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $420.24M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $510.88M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $381.54M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $111.75M | Mar 6, 2024 |
| FY2022 | Dec 31, 2019 | $2.38M | Mar 16, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($815.94M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($633.38M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($344.24M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($242.53M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($157.78M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($80.71M) | Mar 29, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $156.69M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.68M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $73.41M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $63.89M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $33.42M | Mar 6, 2024 |
| FY2021 | Dec 31, 2020 | $64.49M | Mar 29, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $249.55M | Mar 16, 2023 |
| FY2022 | Dec 31, 2021 | $249.55M | Mar 16, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 16, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 16, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 180.28M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 173.57M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 164.28M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 163.55M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 127.65M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 29, 2022 |